On the recordSeptember 30, 2020
This committee's investigation shines a spotlight on the ways that drug companies use litigation as a key part of their strategic plans to delay generic entry.
Source
congress.govEditor's note · Context
Wasserman Schultz discusses drug companies' tactics to maintain high prices through litigation.
Share
More from Debbie Wasserman Schultz
Jul 12, 2025
They are essentially packed into cages, wall to wall humans, 32 detainees per cage.
Jul 6, 2025
Again, more Trump lies, more people being thrown into a dire situation where many of them will ultimately die when they’re deported back to countries like Venezuela and Haiti, which clearly don’t have conditions in which it is safe or a…
Mar 31, 2025
It is with a heavy heart that I rise to honor the life, the work and the legacy of Congressman Raul Grijalva. While others rush to punch down on people who chase a better life, he was always a brave, bold voice for Tribes, workers and…
Other voices in this conversation
